Search | Clinical Trials Finder

Conditions: Plaque Psoriasis
Interventions: Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 20
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • North Little Rock, Arkansas + 16 more

Conditions: Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, Neoplasm Metastasis, Nervous System Neoplasms
Interventions: ABT-888, Whole Brain Radiation Therapy; Drug · Radiation
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 99 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 7
States / cities: Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas + 4 more

Conditions: Seizures
Interventions: Placebo, CVL-865; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 37
States / cities: Little Rock, Arkansas • Downey, California • Loma Linda, California + 33 more

Conditions: Multiple Myeloma
Interventions: Dexamethasone, Daratumumab, Venetoclax, Bortezomib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 14
States / cities: Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 10 more

Conditions: Parkinson's Disease
Interventions: ABBV-0805, Placebo ABBV-0805; Drug
Lead sponsor: AbbVie; Industry
Eligibility: Up to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 5
States / cities: Gainesville, Florida • New York, New York • Durham, North Carolina + 2 more

Conditions: Psoriasis
Interventions: BI 655066 (very high i.v. dose), Placebo, i.v., BI 655066 (high s.c. dose), BI 655066 (low i.v. dose), BI 655066 (high medium i.v. dose), BI 655066 (very low i.v. dose), BI 655066 (low s.c. dose), BI 655066 (high i.v. dose), Placebo, s.c., BI 655066 (low medium i.v. dose); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Burbank, California • Miami, Florida • Port Orange, Florida + 4 more

Conditions: Hidradenitis Suppurativa, Atopic Dermatitis
Interventions: Lutikizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Sacramento, California • Ann Arbor, Michigan

Conditions: Breast Cancer, Cancer
Interventions: Venetoclax, Capecitabine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 11
States / cities: Joliet, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 7 more

Conditions: Colorectal Cancer
Interventions: Telisotuzumab adizutecan, Bevacizumab, Trifluridine/Tipiracil; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 990 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Goodyear, Arizona • Springdale, Arkansas • Duarte, California + 15 more

Conditions: Atopic Dermatitis
Interventions: Upadacitinib (ABT-494); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 15
States / cities: Huntington Beach, California • Los Angeles, California • Coral Gables, Florida + 12 more

Conditions: Exocrine Pancreatic Insufficiency (EPI)
Interventions: Pancrelipase, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 21 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 27 more

Conditions: DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL, MCL, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL), Indolent B-cell Non-Hodgkin Lymphoma (iNHL), Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)
Interventions: Epcoritamab; Biological
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 17
States / cities: Phoenix, Arizona • San Francisco, California • Denver, Colorado + 14 more

Conditions: Generalized Anxiety Disorder
Interventions: Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day, Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 36
States / cities: Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more

Conditions: Migraine
Interventions: Ubrogepant 100 mg, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 73
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 65 more

Conditions: Advanced Solid Tumors
Interventions: ABT-348, ABT-348 and carboplatin, ABT-348 and docetaxel; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Chicago, Illinois • Houston, Texas

Conditions: Chronic Hepatitis C, Hepatitis C Virus (HCV) Infection
Interventions: ABT-267, Pegylated interferon (pegIFN), Ribavirin (RBV), Placebo for ABT-267; Drug · Other
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 7 more

Conditions: Advanced Parkinson's Disease
Interventions: Levodopa carbidopa intestinal gel (LCIG), Placebo gel, Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube; Drug · Device
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 30 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 8
States / cities: Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 5 more

Conditions: Small Cell Lung Cancer
Interventions: Ipilimumab, Nivolumab, Rovalpituzumab tesirine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 15
States / cities: La Jolla, California • Orlando, Florida • Athens, Georgia + 11 more

Conditions: Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML
Interventions: Posaconazole, ABT-199, Decitabine, Azacitidine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 60 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 13
States / cities: Duarte, California • Sacramento, California • Aurora, Colorado + 8 more

Conditions: Multiple Myeloma
Interventions: Etentamig, Lenalidomide, Dexamethasone, Daratumumab, Carfilzomib, Mezigdomide, Iberdomide, ABBV-2001, Pomalidomide; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 15
States / cities: Duarte, California • Irvine, California • San Francisco, California + 11 more

Conditions: Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer
Interventions: Azirkitug, Budigalimab, Bevacizumab, Telisotuzumab Adizutecan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 694 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 20
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 15 more

Conditions: Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Rituximab, Venetoclax; Procedure · Biological · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Interventions: ABT-957, Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Cypress, California • Orlando, Florida • The Villages, Florida + 6 more

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Azacitidine, Venetoclax, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 24
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 17 more

Search by objective public record fields.

A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab

A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone

Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants

ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors

Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy